Bandola-Simon Joanna, Ito Yoshinaga, Wucherpfennig Kai W, Roche Paul A
Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Institute for Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
Cell Rep. 2025 Jan 28;44(1):115150. doi: 10.1016/j.celrep.2024.115150. Epub 2025 Jan 2.
Tumor-draining lymph node dendritic cells (DCs) are poor stimulators of tumor antigen-specific CD4 T cells; however, the mechanism behind this defect is unclear. We now show that, in tumor-draining lymph node DCs, a large proportion of major histocompatibility complex class II (MHC-II) molecules retains the class II-associated invariant chain peptide (CLIP) fragment of the invariant chain bound to the MHC-II peptide binding groove due to reduced expression of the peptide editor H2-M and enhanced activity of the CLIP-generating proteinase cathepsin S. The net effect of this is that MHC-II molecules are unable to efficiently bind antigenic peptides. DCs in mice expressing a mutation in the invariant chain sequence that results in enhanced MHC-II-CLIP accumulation are poor stimulators of CD4 T cells and have diminished anti-tumor responses. Our data reveal a previously unknown mechanism of immune evasion in which enhanced expression of MHC-II-CLIP complexes on tumor-draining lymph node DCs limits MHC-II availability for tumor peptides.
肿瘤引流淋巴结中的树突状细胞(DCs)是肿瘤抗原特异性CD4 T细胞的低效刺激物;然而,这种缺陷背后的机制尚不清楚。我们现在发现,在肿瘤引流淋巴结DCs中,由于肽编辑器H2-M表达减少和产生CLIP的蛋白酶组织蛋白酶S活性增强,很大一部分主要组织相容性复合体II类(MHC-II)分子保留了与MHC-II肽结合槽结合的恒定链的II类相关恒定链肽(CLIP)片段。其最终结果是MHC-II分子无法有效结合抗原肽。在恒定链序列中表达突变导致MHC-II-CLIP积累增强的小鼠DCs是CD4 T细胞的低效刺激物,并且抗肿瘤反应减弱。我们的数据揭示了一种以前未知的免疫逃逸机制,其中肿瘤引流淋巴结DCs上MHC-II-CLIP复合物的表达增强限制了MHC-II对肿瘤肽的可用性。